Metabolic dysfunction-associated fatty liver disease： A central hub in systemic metabolic dysregulation
- VernacularTitle:代谢相关脂肪性肝病： 全身代谢性紊乱的核心枢纽之一
- Author:
Meng ZHOU
1
;
Tao BO
1
;
Xiude FAN
1
;
Jiajun ZHAO
1
Author Information
- Publication Type:Journal Article
- Keywords: Metabolic Dysfunction-associated Fatty Liver Disease; Metabolic Syndrome; Insulin Resistance
- From: Journal of Clinical Hepatology 2025;41(9):1725-1728
- CountryChina
- Language:Chinese
- Abstract: The prevalence rate of metabolic associated fatty liver disease （MAFLD） is steadily increasing worldwide， and MAFLD is now considered a significant risk factor for a wide range of metabolic comorbidities. However， current clinical management strategies often address MAFLD from a single-disease perspective， lacking a comprehensive understanding of the central role and systemic impact of MAFLD in the prevention and control of metabolic comorbidities. This article reviews the current evidence supporting MASLD as both a trigger and a key node in systemic metabolic dysfunction and elaborates on how hepatic insulin resistance， lipotoxic injury， inflammatory responses， and dysregulation of hepatokines mediate organ-specific metabolic disorders including cardiovascular disease， chronic kidney disease， and diabetes. With reference to the latest national and international guidelines， this article proposes an integrated multidisciplinary management strategy， including liver-glucose joint intervention and a cross-organ “cardio-renal-hepatic” strategy， and it also advocates for a paradigm shift from conventional liver-focused management toward liver-centered systemic metabolic control， in order to effectively delay the progression of MAFLD and its related multisystem complications.
